Home › Find a Research Study

Study Title: Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer
Category: Cancer, General

Currently accepting participants?
Not at this time.

Principal Investigator: Thomas Malpass
Study Coordinator: Kathy Rabena
Phone: (206) 223-6892 Ext.36892
Email: Katherine.Rabena@vmmc.org

What is the Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer study?

An Open Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 eery 21 Days)Hymcantin in Combination with Carboplatin(Day 1 every 21 dys) as Second-Line Therapy in Subjects with Potemtially Platinum-Sensitive Relapsed Ovarian Cancer

Who can participate?

Eligibility: ~Patients with recurrent epithelial ovarin, fallopian tube, or primary peritoneal cancer. ~Has received one prior platinum-based chemotherapeutic regimen (containing either carboplatin or cisplatin) for the treatment of primary disease. ~Patient's disease is considered potentially platinum-sensitive. ~Must have atleast one measurable lesion as determined by diagnostic studies including CT or MRI or physical exam. Ineligibility: ~Pregnant or lactating ~Received morn that 1 prior chemotherapy regimen or a histery of consolidation cytotoxic chemotherapy ~Has brain metasteses ~Received prior treatment with Hymcantin

Study Summary:

An Open Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 eery 21 Days)Hymcantin in Combination with Carboplatin(Day 1 every 21 dys) as Second-Line Therapy in Subjects with Potemtially Platinum-Sensitive Relapsed Ovarian Cancer

Detailed Study Description:

(No information)

Study Design: Interventional
Phase of Study: Phase II
Study Type: Interventional
Condition or Study Focus: Ovarian Cancer
Intervention Type: Chemotherapy
Intervention Name: Hymcantin
Gender: Female
Age group: Interventional
Sponsor: GlaxoSmithKline


Other studies in this category include:

Studies currently accepting study participants:

Studies currently not accepting study participants: